• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » bluebird bio, Duke collaborate on value-based payment framework for gene therapy

bluebird bio, Duke collaborate on value-based payment framework for gene therapy

May 23, 2017
CenterWatch Staff

bluebird bio, a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, announced that it will participate in a consortium led by Duke University’s Robert J. Margolis, M.D., Center for Health Policy to develop a broadly-supported path for value-based payment reform models for gene therapies and other innovative treatments.

“bluebird bio is focused on creating gene therapy products that have a dramatic impact on the lives of patients. Understanding the potential value of these treatments across the healthcare system is not easy, but it is critical that we all work together to develop new and effective payment models that work for all stakeholders, especially patients,” said Nick Leschly, chief bluebird. “Duke-Margolis is a national leader in health policy, and this consortium will bring together key stakeholders across healthcare sectors to create pathways for value-based payment. We look forward to the consortium’s ability to not only drive engagement but also help explore more creative, forward looking, and perhaps most importantly, concrete solutions that brings value first and foremost to the patient.”

The consortium—composed of patient advocates, payers, manufacturers, and providers, as well as experts in regulatory science, law, and policy—will collaborate to outline a path forward for payment reform involving innovative therapies, including genomic medicines for rare diseases.

“Moving from payment arrangements based on volume to those based on value is not easy,” said Duke-Margolis director Mark McClellan, M.D., Ph.D. “Our consortium members represent a wide range of perspectives but share a common goal of payment models that encourage innovation, resulting in better outcomes for patients at a sustainable cost.”

The initial phase of the project is expected to be completed in 2017.

Upcoming Events

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • InputinLights-360x240.png

    Seeking Patient Input Early Helps Ensure Minority Participation in Trials

  • Oncology-360x240.png

    Global Oncology Trial Launches Drop Dramatically During Pandemic, Study Shows

  • Qualification-360x240.png

    Sites and Sponsors Streamlining Qualification Efforts with Technology, Process Revisions

  • New Algorithm Tested and Validated by CSDD Highly Predictive of Patient Burden

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing